سعر سوليتراكت مركب 6/0.4 مجم 2026

Fixed-dose modified-release film-coated tablet of solifenacin succinate 6 mg and tamsulosin hydrochloride 0.4 mg by EVA Pharma.

• Moderate to severe storage and voiding symptoms of benign prostatic hyperplasia in men not adequately responding to monotherapyPopulation: Adult menelectronic medicines compendium (eMC)

• Most frequent: dry mouth (9.5%), constipation (3.2%), dyspepsia including abdominal pain (2.4%); other common: dizziness, blurred vision, fatigue, ejaculation disorder including retrograde ejaculation. Acute urinary retention (0.3%) is the most serious reaction seen in studies.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity; haemodialysis; severe hepatic impairment; severe renal impairment or moderate hepatic impairment with a strong CYP3A4 inhibitor (e.g. ketoconazole); severe gastrointestinal conditions (including toxic megacolon), myasthenia gravis, narrow-angle glaucoma or risk of these; history of orthostatic hypotension.International label, same formulation · electronic medicines compendium (eMC)

• Caution in severe renal impairment, risk of urinary retention, gastrointestinal obstruction or reduced motility, hiatus hernia/reflux, autonomic neuropathy. Exclude other causes of symptoms and treat urinary tract infection first.International label, same formulation · electronic medicines compendium (eMC)
• QT prolongation and torsade de pointes reported with solifenacin in patients with risk factors; angioedema and anaphylaxis reported (discontinue permanently); blood pressure reduction and rarely syncope with tamsulosin.International label, same formulation · electronic medicines compendium (eMC)

• Anticholinergic medicinesMore pronounced therapeutic and undesirable effects; allow about one week after stopping before starting other anticholinergic therapy.electronic medicines compendium (eMC)
• Strong CYP3A4 inhibitors (ketoconazole, ritonavir, nelfinavir, itraconazole)Increase exposure to both solifenacin and tamsulosin; use with caution, and do not combine in CYP2D6 poor metabolisers or patients on strong CYP2D6 inhibitors.electronic medicines compendium (eMC)
• Cholinergic receptor agonistsMay reduce the therapeutic effect of solifenacin.electronic medicines compendium (eMC)

• Not indicated for use in women (pregnancy and lactation).International label, same formulation · electronic medicines compendium (eMC)

English text not available for this section.